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OBJECTIVES: Dengue cases range from asymptomatic to severe, eventually leading to hospitalization and death.
Timely and appropriate management is critical to reduce morbidity. Since 1980, dengue has spread throughout
Brazil, affecting an increasing number of individuals. This paper describes age and regional differences in
dengue’s clinical presentation and associated risk of hospitalization based on more than 5 million cases
reported to the Brazilian Ministry of Health from 2000-2014.
METHODS: We performed a retrospective analysis of B5,450,000 dengue cases, relating clinical manifestations
and the risk of hospitalization to age, gender, previous infection by dengue, dengue virus serotype, years of
formal education, delay to first attendance and the occurrence of dengue during outbreaks and in different
Brazilian regions.
RESULTS: Complicated forms of dengue occurred more frequently among those younger than 10 years (3.12%
vs 1.92%) and those with dengue virus 2 infection (7.65% vs 2.42%), with a delay to first attendance 42 days
(3.18% vs 0.82%) and with p4 years of formal education (2.02% vs 1.46%). The risk of hospitalization was
higher among those aged 6-10 years old (OR 4.57; 95% CI 1.43-29.96) and those who were infected by dengue
virus 2 (OR 6.36; 95% CI 2.52-16.06), who lived in the Northeast region (OR 1.38; 95% CI 1.11-2.10) and who
delayed first attendance by 45 days (composite OR 3.15; 95% CI 1.33-8.9).
CONCLUSIONS: In Brazil, the occurrence of severe dengue and related hospitalization is associated with being
younger than 10 years old, being infected by dengue virus 2 or 3, living in the Northeast region (the poorest and
the second most populated) and delaying first attendance for more than 2 days.
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’ INTRODUCTION
Over the past 50 years, dengue has become one of the
top priorities of the World Health Organization (WHO) in
terms of global health. This infection occurs in more than
100 countries and is estimated to affect 50-100 million people,
with 500,000 severe cases demanding hospitalization and
approximately 20,000 deaths every year (1). More than
200 disability-adjusted life years per million population are
lost per year (2), with an estimated cost ranging from US$248-
571 for ambulatory and hospitalized cases in certain Asian and
Latin American countries, implying an annual cost as high as
US$500-1000 million per year in countries such as Brazil (3).
Since its reappearance in Brazil in the early 1980s, dengue
has progressively spread throughout the country, affecting
an increasing number of individuals, states and municipa-
lities (3-7). Initially, it presented as recurrent yearly epidemics
with a relatively small number of cases that affected different
regions of the country and that occasionally spared the same
region one year but not another. However, the increasing
circulation of various serotypes of the virus has been
associated with increases in the frequency and extent of
epidemics, with increasing numbers of complicated dengue
cases and hospitalizations (3-6).
Human infection by dengue virus (DENV) leads to a wide
spectrum of clinical presentations, often with unpredictableDOI: 10.6061/clinics/2016(08)08
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clinical evolution and outcomes (8). Classic dengue fever
(DF) is an acute febrile illness, with a sudden onset of fever
typically after 5-7 days (full range from 3-12 days) of
incubation. The accompanying symptoms are uncharacter-
istic and the most frequently reported findings are headache
and generalized muscular, articular and osseous pain.
Occasionally, retro-orbital pain; photophobia; a mild macu-
lopapular skin rash; and minor hemorrhagic manifestations,
such as petechiae, ecchymosis, epistaxis and positive
tourniquet testing, are also reported (8-10).
However, a small proportion (B5%) of patients may
present or evolve to more severe clinical forms, mostly
characterized by plasma leakage with or without hemor-
rhage, known as dengue hemorrhagic fever (DHF); dengue
shock syndrome (DSS); or other complicated clinical forms
that have significant morbidity and mortality (8-10). Warning
signs of progression to severe dengue usually occur after the
first few days of the febrile disease and include severe
abdominal pain; persistent vomiting; difficulty breathing;
signs of hypovolemic shock; a rapid decline in the platelet
count and an increase in hematocrit of at least 10%, with or
without mucosal bleeding (8-10).
Early clinical findings are nonspecific and demand a high
index of suspicion because recognizing the early signs of
potential complications or shock and promptly initiating
intensive supportive therapy can reduce the risk of death
among patients with severe dengue from 10% to o1% (8,9).
This is particularly important during dengue outbreaks,
when health services need to cope with the sudden surge in
demand (8,9).
In this paper, we present a clinical-epidemiological
description of dengue in Brazil based on a reanalysis of
nearly 5,450,000 dengue cases reported to the National
Epidemiological Surveillance Secretary (SVS) of the Brazilian
Ministry of Health (MoH) and assessed by the Brazilian
national reportable disease information system, named
SINAN (Sistema de Informac¸ão de Agravos de Notificac¸ão)
(11), from 2000-2014. This analysis focuses specifically on
age, gender, DENV serotype, the time to first attendance, the
number of years of formal education and regional differences
in the clinical presentation of dengue and risk factors related
to hospitalization.
In 1997, the WHO proposed the grouping of symptomatic
DENV infections into three categories: undifferentiated fever,
DF and DHF. DHF was further classified into four severity
grades, with grades III and IV being defined as DSS (8).
However, many have complained that this classification is
difficult to use in different clinical settings (12-14), as
summarized in a systematic literature review (15). More
recently, the WHO conducted a study aimed to ‘‘...devise a
system that identified patients requiring major intervention with
sufficient sensitivity and specificity to be practically useful" (16).
However, as mentioned by the authors, only a small fraction
of cases evolved to severe disease and ‘‘...much larger studies
are necessary to fully characterize features associated with disease
progression" (16). This issue notwithstanding, the results of
the study were incorporated into the 2009-10 WHO
simplified classification for dengue, which defined three
categories: DF, dengue with warning signs and severe
dengue (8,16).
However, the frequency of clinically complicated dengue
cases increased, leading to high morbidity and increased
hospitalization. The cases did not fulfill the strict WHO
criteria for dengue with warning signs or severe dengue,
leading the Brazilian MoH to propose a new category of
severe dengue, named ‘‘dengue with complications’’ (or CD,
an acronym for ‘‘complicated dengue’’) (10). CD was
characterized as all severe dengue cases that did not fulfill
the WHO criteria for dengue with warning signs, DHF or
DSS and those that presented with any one of the following
signs and symptoms: severe alterations in the central
nervous system (CNS), cardiorespiratory dysfunction, hepa-
tic or renal insufficiency, a platelet count below 20,000/mm3,
gastrointestinal bleeding, pleural effusion or ascites, a global
white blood cell count below 1,000/mm3, or any dengue case
that led to death without having been characterized as DHF
or DSS (10,17). This classification was officially adopted in
Brazil and therefore, the cases notified to SINAN are
classified accordingly.
Previous studies have qualitatively described the occur-
rence of dengue and DHF in Brazil since the early 1980s (18),
but none has provided a systematic analysis of the clinical-
epidemiological-social aspects of dengue occurrence in
Brazil.
Brazil is the fifth largest country in the world in terms of
both territory and population size. It is divided into 26 states
and the Distrito Federal, an independent territory seat for the
federal capital, Brasília and certain surrounding municipa-
lities. The 26 states are grouped into five distinct geographi-
cal regions that share geographical, physical, ethnic, cultural
and economic similarities, known as the North region (with
7 states), the Northeast region (with 9 states), the Southeast
region (with 4 states) and the Central-West and South regions
(with 3 states each) (see Figure 1).
Brazil has drastically urbanized since the mid-1970s and
now, more than 78% of the Brazilian population lives in an
urban setting. The North region is nearly entirely in the
Amazon and most of it is covered by tropical rain forest. The
Northeast region is the poorest in the country and most of it
is in a semi-arid area, with sparse rainfalls and poor socio-
demographic conditions. Meanwhile, the Southeast region is
the most populated and developed region in the country. The
South region is characterized by a moderate climate (colder
than the rest of the country) and therefore has been spared
(with the exception of Paraná state) from dengue epidemics.
Finally, the Central-West region is an area with a rich
agricultural-based economy on the southern border of the
Amazon. Table 1 summarizes several socio-demographic
characteristics of Brazil and its regions (19) that are related
to dengue transmission and to the risk of hospitalization due
to dengue.
’ METHODS
This was a population study based on a secondary
data analysis of dengue morbidity and hospitalization
risk. Unidentified data from dengue cases reported to
the Health Surveillance Secretary of the Brazilian MoH,
as assessed by the Brazilian national reportable disease
information system, named SINAN (Sistema de Infor-
mac¸ão de Agravos de Notificac¸ão) (11) were specifically
analyzed. Since its reintroduction in Brazil in the early
1980s, it is mandatory that all dengue cases are notified to
SINAN (10,18).
According to the Brazilian MoH classification, DF is
defined as an acute febrile illness no more than seven days
long, accompanied by at least two of the following
symptoms: headache, retro-orbital pain, myalgia, arthralgia,
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Figure 1 - Geo-political map of Brazil, with colored representations of its geographic regions (green for North, blue for Northeast,
red for Southeast, yellow for Central-West and orange for South).
Table 1 - Socio-demographic characteristics of the population in Brazil and in the Brazilian regions (19).
Socio-Demographic Characteristic Brazil Brazilian Regions
North Northeast Southeast South Central-West
Estimated population in 2014 203,834,190 16,394,272 57,454,690 85,663,161 29,580,665 14,741,402
Urbanization rate (%) 84.8 74.6 73.3 93.2 85.5 90.1
E Number of dwellings (1000) 57,557 4,010 14,994 25,310 8,993 4,250
% without regular water supply 18.3 44.6 24.0 9.0 11.6 16.2
% without adequate sanitation 44.5 84.8 66.3 14.1 42.1 56.4
% without regular waste collection 14.1 25.8 26.7 4.4 5.8 8.6
% not covered by the family health program 30.1 49.0 35.2 64.1 49.7 50.9
Per capita GDP in US$ PPP (2014) 8,619 5,725 4,203 11,478 9,748 11,845
Gini index 0.526 0.526 0.530 0.511 0.481 0.544
Women’s fecundity rate 1.77 2.22 1.89 1.63 1.62 1.74
Infant mortality rate (per 1,000 born alive) 15.0 19.2 19.4 11.6 10.4 15.6
Life expectancy at birth (years) 74.8 71.5 72.2 76.6 76.9 74.4
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prostration and exanthema, possibly associated with minor
hemorrhagic manifestations. In addition, the patient should
have been in an area with active dengue transmission in the
last 15 days (10).
All reported dengue cases that occurred in municipalities
in which dengue epidemics occurred in the period from
2000-2014 were selected for this analysis. A dengue epidemic
was defined as the period of time in which the following
conditions were simultaneously satisfied:
1. Having had three consecutive weeks with an increasing
number of cases;
2. The first week of the outbreak was the first in which the
number of cases surpassed the 95% upper limit of
the confidence interval of the average number of cases
in the previous 5 weeks; and
3. The last week of the epidemic was the first in which the
number of cases dropped below the previously mentioned
limit after three consecutive weeks with a decreasing
number of cases.
The resulting database comprised 5,444,285 dengue cases,
corresponding to nearly 80% of the total dengue cases
reported to the Brazilian MoH in the study period. The
other B20% of cases occurred in municipalities without
dengue epidemics in the period analyzed (as defined above).
The clinical manifestations of dengue at presentation were
related to age, gender, previous infection by DENV, DENV
serotype and Brazilian geographic region and were
expressed as absolute counts and percentages of patients
who presented with each of the symptoms and signs
reported. The prevalence of dengue, DHF, DSS and CD, as
defined by the Brazilian MoH, were also related to the same
variables. Finally, the risk of hospitalization was related to
the same variables and to years of formal education, delay to
first attendance (in days), a previous dengue episode and
whether the dengue case occurred during an outbreak/
epidemic.
Associations between variables were assessed by means of
chi-square and Bonferroni tests and a multivariate logistic
regression analysis was performed to identify the main risk
factors related to hospitalization. The analysis was con-
ducted using Statistica 64 (V12)s, StatSoft, INC. and the
significance level was set at 5%.
Ethics Statement
This research involved the use of anonymized patient
medical data extracted from the Brazilian reportable disease
information system and was approved by the Ethics in
Research Committee of the Federal University of São Paulo,
Brazil (#2059131213).
’ RESULTS
Figure 2 shows the occurrence of dengue as related to the
main serotypes involved and the epidemiological week per
year between 2000 and early 2014, and Figure 3 shows the
successive dengue epidemics as related to the age classes
affected during the period from 2000-2014.
Figure 2 - Dengue occurrence per epidemiological week and serotype in Brazil from 2000-2014.
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Table 2 shows the frequency of dengue symptoms as
related to the selected variables. Fever was experienced by
approximately 95-97% of the patients. Headache was
experienced by approximately 90% but showed some
variation, with lower frequency among children below
10 years of age and adults above 65 years. Headaches were
also less pronounced in males and in people from the North
and Northeast regions. In contrast, diarrhea and rash were
the least frequent symptoms and showed marked differences
(21-45%) in their frequency among the distinct classes of
variables. Rash was more frequent in children younger than
5 years old, those infected by DENV 1 and those living in the
North region. Meanwhile, diarrhea was more frequent
among adults older than 50 years and those living in the
North region. The others symptoms varied in frequency from
38-88%, showing marked variations among the different
groups (see Table 2 for details).
Table 3 shows the number of dengue cases and the
frequency of its different clinical forms as related to the
selected variables. It is noteworthy that the highest frequen-
cies of CD, DHF and DSS were related to younger age
classes, DENV types 2 and 3, the North and Northeast
regions, a delay to first attendance greater than 3 days and
less than 4 years of formal education.
Table 4 shows the univariate analysis of the risk of
hospitalization as related to the selected variables. During
the period analyzed, 113,726 patients with age information
were hospitalized, with B60% of them aged from 11-50
years. This finding notwithstanding, the highest proportion
of hospitalizations was observed among the youngest
patients, with more than 15% of children younger than
10 years old being hospitalized. Additionally, a relatively
high proportion of elders (465 years old) were hospitalized
(12.4%) due to dengue. Regarding the DENV serotypes, the
highest proportion of hospitalizations (25.5%) was related to
DENV 2, followed by DENV 3 (16.8%). The Northeast region
was the region with the highest (13.5%) hospitalization rate
in Brazil. Delaying the first attendance by more than two
days was related to an increase in the risk of hospitalization
(the risk nearly tripled for delays between 3-5 days and
nearly quintupled for delays greater than 5 days). Having
had less than four years of formal education increased the
risk of hospitalization by 1.5 times. Finally, having had
dengue during a period not defined as a dengue epidemic
nearly doubled the risk of hospitalization.
Table 5 shows a summary of the multivariate analysis of
the risk of hospitalization due to dengue. All variables
described in Table 4 were included in the logistic model, as
they were all significantly associated with the risk of
hospitalization. It is noteworthy that those aged less than
5 years had nearly triple the risk and that those aged
between 6-10 years had nearly quintuple the risk. Moreover,
Figure 3 - Successive dengue epidemics in Brazil from 2000-2014, as related to the affected age class and year of occurrence.
459
CLINICS 2016;71(8):455-463 Dengue hospitalization risk in Brazil
Burattini MN et al.
Table 2 - Frequency of dengue symptoms at presentation, as related to the selected variables.
Fever Headache Rash Generalized Pain Prostration Myalgia Arthralgia Nausea Diarrhea
Age (years)
1-5 95.4% 68.1% 49.6% 42.1% 60.1% 56.2% 37.5% 52.9% 26.7%
6-10 96.2% 87.5% 40.3% 59.5% 66.3% 69.6% 49.5% 59.5% 21.7%
11-20 96.2% 92.5% 36.0% 73.2% 70.5% 81.0% 62.8% 59.3% 22.9%
21-35 95.9% 93.4% 37.6% 77.1% 71.6% 86.0% 70.9% 61.2% 26.3%
36-50 96.0% 92.9% 41.8% 77.3% 74.2% 87.6% 74.2% 62.2% 29.2%
51-65 95.8% 91.5% 40.0% 73.9% 75.5% 87.6% 74.8% 63.0% 31.7%
465 94.6% 88.1% 33.8% 67.8% 74.5% 85.7% 72.4% 60.0% 30.8%
Gender
Female 93.5% 90.3% 40.1% 72.7% 69.3% 82.6% 67.5% 62.1% 26.3%
Male 94.3% 88.5% 34.0% 68.9% 67.3% 80.7% 64.2% 52.7% 25.7%
DENV Serotype
DENV 1 97.4% 92.4% 45.1% 76.3% 76.4% 83.6% 73.8% 53.3% 22.7%
DENV 2 95.0% 92.6% 33.2% 76.3% 76.4% 85.0% 72.4% 57.3% 24.1%
DENV 3 98.2% 92.9% 33.0% 75.3% 74.5% 86.9% 72.5% 59.1% 23.1%
DENV 4 96.3% 92.2% 36.1% 73.4% 72.8% 83.3% 72.6% 64.4% 22.3%
Brazilian Region
North 94.4% 89.6% 41.9% 71.4% 53.5% 81.6% 71.1% 52.9% 29.7%
Northeast 88.3% 83.4% 36.8% 61.6% 53.1% 73.4% 55.3% 47.3% 21.2%
Southeast 96.7% 93.0% 38.1% 76.8% 80.3% 86.4% 70.2% 65.2% 27.9%
Central-West 97.3% 92.1% 31.9% 74.0% 79.9% 86.0% 73.4% 64.1% 27.3%
South 94.7% 92.5% 31.5% 71.2% 77.5% 86.2% 67.1% 65.9% 24.5%
Previous Dengue
Yes 97.6% 95.7% 36.7% 82.2% 77.5% 87.3% 75.6% 65.4% 29.2%
No 97.3% 93.0% 40.7% 76.5% 74.5% 85.3% 71.0% 61.8% 28.2%












1-5 158616 96.87% 2.29% 0.83% 0.02%
6-10 258372 94.75% 3.94% 1.28% 0.02%
11-20 801997 97.65% 1.85% 0.49% 0.01%
21-35 1270950 98.37% 1.32% 0.30% 0.01%
36-50 879684 98.02% 1.59% 0.38% 0.01%
51-65 462687 97.57% 2.00% 0.41% 0.02%
465 163873 96.54% 2.86% 0.56% 0.04%
Gender
Female 2408847 97.77% 1.76% 0.46% 0.01%
Male 1913157 97.47% 2.01% 0.50% 0.02%
DENV Serotype
DENV 1 11546 95.96% 2.41% 1.51% 0.13%
DENV 2 2711 85.57% 7.65% 5.53% 1.25%
DENV 3 4416 91.04% 5.59% 3.15% 0.22%
DENV 4 3922 95.73% 2.45% 1.20% 0.61%
Brazilian Region
North 446450 98.38% 1.03% 0.57% 0.02%
Northeast 999774 97.60% 1.65% 0.73% 0.02%
Southeast 2239451 97.54% 2.09% 0.35% 0.01%
Central-West 547436 97.25% 2.17% 0.57% 0.01%
South 90775 99.38% 0.36% 0.25% 0.01%
Previous Dengue
Yes 105965 90.7% 1.3% 0.6% 0.0%
No 786398 93.1% 1.0% 0.4% 0.0%
Delay to First Attendance
(days)
0-2 1312749 99.01% 0.82% 0.16% 0.01%
3-5 964121 97.33% 2.10% 0.55% 0.02%
6-7 345171 95.21% 3.71% 1.05% 0.03%
47 328240 95.86% 3.20% 0.91% 0.03%
Years of Formal Education
p4 years 336604 97.17% 2.02% 0.79% 0.01%
44 years 1801282 98.06% 1.46% 0.46% 0.01%
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people older than 65 years had nearly double the risk of
hospitalization, although this result was not significant in the
multivariate analysis. With respect to dengue serotypes,
DENV 2 was associated with a six times higher risk of
hospitalization than for DENV 4, while DENV 3 was
associated with a nearly two times higher risk than for
DENV 4. In contrast, DENV 1 was associated with only one
third of the risk of hospitalization for DENV 4 (this result
was not significant in the multivariate analysis). With respect
to the different Brazilian regions, the Northeast region was
associated with a 38% higher risk of hospitalization relative
to the South region. In contrast, both the Southeast and the
Central-West regions had lower risks (88% and 41%,
respectively) of hospitalization compared with the South
region. Finally, delaying the first attendance by more than
7 days was associated with a nearly four times higher risk of
hospitalization compared with a delay of less than 2 days. In
addition, compared with a delay of less than 2 days, a delay
between 5 and 7 days increased the risk by 2.5 times.
’ DISCUSSION
Infection by any serotype of DENVresults in a large spectrum
of nonspecific clinical manifestations with an unpredictable
clinical course and outcome, ranging from asymptomatic cases
to severe clinical forms leading to hospitalization, a need for
intensive care treatment and death. Timely and appropriate
monitoring and clinical management of dengue patients, mainly
entailing early fluid replacement interventions, is critical to
reduce morbidity and mortality (8,10).
DENV and its vectors are now widely distributed
throughout tropical and subtropical regions, spreading
particularly over the last half-century and threatening even
temperate regions, such as North America and Europe (20).
Throughout the world, the significant geographic expansion
of dengue has been coupled with rapid increases in the
numbers of cases and epidemics, leading to an increasing
number of more severe forms of dengue, hospitalizations
Table 4 - Results of the univariate analysis of the risk of
















Female 61541 7.68% o0.0001
Male 55389 8.50%
DENV Serotype
DENV 1 708 11.55% o0.001
DENV 2 309 25.52%
DENV 3 313 16.84%
DENV 4 267 8.55%
Brazilian Region






Yes 50404 10.69% o0.0001
No 369147 10.42%
Delay to First Attendance
(days)




Years of Formal Education
p4 years 11712 11.41% o0.0001
44 years 31812 7.67%
During Outbreak/Epidemic
Yes 90576 6.96% o0.0001
No 77101 12.21%
Table 5 - Summary of the multivariate analysis of the risk of hospitalization due to dengue, as related to the selected variables.
Odds Ratio Lower 95% CI Upper 95% CI p-value
Intercept 1 14.05 7.74 25.51 0.0001
Age (years)
1-5 2.87 1.40 5.86 0.0385
6-10 4.57 1.43 29.96 0.0039
21-35 1.00 --- --- ---
36-50 1.31 0.76 2.84 0.1035
465 1.81 0.90 3.64 0.0958
DENV Serotype
DENV 1 0.32 0.22 2.14 0.0747
DENV 2 6.36 2.52 16.06 0.0001
DENV 3 1.94 1.17 3.20 0.0100
DENV 4 1.00 --- --- ---
Brazilian Region
South 1.00 --- --- ---
Southeast 0.12 0.08 0.18 0.0001
Central-West 0.59 0.43 0.82 0.0018
Northeast 1.38 1.11 2.10 0.0138
Delay to First Attendance (days)
0-2 1.00 --- --- ---
3-5 0.40 0.28 1.72 0.0871
6-7 2.49 1.33 4.66 0.0044
47 3.62 1.62 8.09 0.0017
Obs: Only the variable categories that remained in the final model are shown.
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and deaths (20). In the Southeast Asia (SEA) and Western
Pacific (WP) regions, the expansion of dengue has occurred
over the past few decades; epidemics are occurring persis-
tently in regular 3- to 5-year cycles, with an increasing
number of reported cases in many countries that are now
classified as hyperendemic and all four DENV serotypes
being reported as present (20). Severe dengue is endemic in
most SEA countries and is a leading cause of hospitalization
and death in children from the region, which has reported
rates of severe dengue up to 18 times higher than in the
Americas (20).
Also in the Americas, dengue transmission resurged in the
late 1970s, and now many countries are hyperendemic, with
epidemics occurring cyclically every 3-5 years, as in SEA;
these epidemics are also increasing in frequency and size,
particularly in Latin America (20). Similarly, since the early
1980s, dengue has spread throughout Brazil, occurring as
annual recurrent seasonal epidemics mainly in the summer,
with an increasing number of complicated cases and
hospitalizations. All four serotypes of DENV circulate in
Brazil, and there is a clear tendency towards an increase in
the number of children and youth affected (see Figure 3), as
previously observed in SEA. In 2013 and 2015 two of the
largest epidemics of dengue ever recorded in a single country
occurred in Brazil, with both involving more than 1,300,000
cases and with the second peaking at more than 1,600,000
cases notified to the Brazilian MoH (11).
This paper describes age and regional differences in the
clinical presentation of dengue among more than 5.4 million
cases reported to the SINAN in the period between 2000 and
2014. It also presents an analysis of the risk of hospitalization
due to dengue. We found that the highest frequencies of CD,
DHF and DSS were related to younger age classes, to DENV
types 2 and 3, to the North and Northeast regions, to a delay
to first attendance greater than 2 days and to less than
4 years of formal education. In addition, being younger than
10 years old nearly quintupled the risk of hospitalization.
Infection by DENV 2 was associated with a risk of
hospitalization six times larger than that for DENV 4, and
DENV 3 was associated with a risk nearly twice as large as
for DENV 4. Regarding the different Brazilian regions, the
Northeast region was associated with a 38% increase in
the risk of hospitalization relative to the South region. In
contrast, both the Southeast and the Central-West regions
had lower risks (88% and 41%, respectively) of hospitaliza-
tion. Finally, delaying the first attendance by more
than 5 days was associated with a nearly four times greater
risk of hospitalization compared with a delay of less than
2 days.
Dengue usually presents as recurrent, seasonal, yearly
epidemics, which may increase the awareness of the health
sector, which may in turn promptly suspect and identify
clinical cases (4). However, Brazil is a large country, with
dengue occurring differently in different regions, states and
municipalities (4-6). In certain areas, recurrent yearly dengue
epidemics and outbreaks are common, occurring approxi-
mately during the same period year after year. In other
regions, however, dengue presents as irregular large epi-
demics occurring sparsely over time and with a large
number of cases occurring year round (but mainly through-
out the summer and autumn), but without relation to
recognizable outbreaks or epidemics. In these regions, the
clinical awareness that prompts dengue suspicion and
diagnosis may not be as present as needed. Whether dengue
occurred during an outbreak/epidemic seems to be an
important factor, with our study showing that the risk of
hospitalization nearly doubles for dengue cases not related to
recognizable outbreaks/epidemics. This finding indicates
per se the need for adequate descriptions of age, gender and
regional differences in the clinical presentation of dengue, as
presented in this paper.
Timely and appropriate monitoring and clinical manage-
ment of dengue cases depend on many parameters; among
the most important are the socio-educational level of the
population, the clinical awareness of physicians and other
health personnel and the adequate infrastructure of the
health system. Our results, sadly but not surprisingly, point
to the Northeast region, which is the poorest and the second
most populated in the country, as the region with the highest
risk of hospitalization due to dengue. It is followed by the
North region, which is nearly equally poor and destitute of
basic conditions for adequate population care. Health
conditions related to impoverishment and low socio-
economic development, such as malnutrition and poor
urban conditions and public services (including poor waste
collection, water supply and sanitation), together with a poor
basic public health structure constitute a nearly ideal
amalgam for the breeding of Aedes spp. mosquitoes and
the development of severe dengue cases as dengue outbreaks
and epidemics subsequently occur.
Previous studies have described and critically commented
on the clinical presentation of dengue in Brazil and elsewhere
(12,14,18). Socio-demographic characteristics have also been
previously studied in relation to the occurrence of dengue,
but not in relation to its clinical presentation or the risk of
hospitalization due to dengue (21-25). Therefore, to the best
of our knowledge, this is the first study to systematically
analyze and describe regional differences in dengue’s clinical
presentation and associated risk of hospitalization and to
relate these different presentations and outcomes to distinct
socio-demographic variables.
Certain limitations of this study are related to its retro-
spective nature because information related to important
data may be incomplete, which is a typical limitation of this
type of study. In addition, several other important character-
istics, such as nutritional status and individual socio-
economic variables, that could be associated with the risk
of hospitalization could not be assessed in the present
analysis. Finally, dengue mortality and the risk factors
related to the lethality of dengue were not analyzed here,
as they will be specifically analyzed in a future publication.
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